Presentation from OIS@ASCRS 2017 Yari Mitchell, VP, Global Medical Affairs & Business Strategy

1. Transforming Vision
With Small Aperture Optics
Yari L. Mitchell
Vice President, Medical Affairs & Business Strategy
OIS@ASCRS – May 4, 2017

2. W o r d s
W o r d s
W o r d s
W o r d s
Y o u r W h o l e W o r l d
W o r d s

5. Single Focus Challenge
20/16 at Far
20/50 at Intermediate
20/100 at Near
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
2.00 1.50 1.00 0.50 0.00 -0.50 -1.00 -1.50 -2.00 -2.50 -3.00 -3.50 -4.00
LogMARAcuity
Defocus (D)
Defocus Curve
Mean BCDVA
Functional
Range of
Vision
* Presbyopic patient defocus curve – KAMRA Inlay PMA (N=114)

6. Benefits of Small Aperture
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
-4.00-3.50-3.00-2.50-2.00-1.50-1.00-0.500.000.501.001.502.00
LogMARAcuity
Defocus (D)
Binocular Defocus Curve (IC-8® IOL with Monofocal IOL)
* Mean BSCVA defocus curve collected in a subgroup at 6 months (N=12)
Functional
Range of
Vision
20/20 at Intermediate
20/30 at Near
20/16 at Far

7. Quantity and Quality
0.0D +0.5D +1.0D +1.5D +2.0D +3.0D
IC-8® IOL
Target-corrected
to -0.75D
Symfony IOL
AcriLisa
Trifocal IOL
(Far Focus) (Near Focus)(Intermediate Focus)

8. The IC-8 IOL is not approved for use in the United States
KAMRA® Inlay IC-8® Intraocular Lens

9. Creating the Corneal Inlay Market

10. KAMRA® Inlay in the Real World
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Preop Month 1 Month 3 Month 6
LogMARAcuity
Visit
UCDVA
UCDVA IE UCDVA OU
-0.20
-0.10
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
Preop Month 1 Month 3 Month 6
LogMARAcuity
Visit
UCNVA
UCNVA IE UCNVA OU
N=337 N=248N=328N=271

11. KAMRAInlay

12. Taking Share in a Crowded IOL Market

13. Uncorrected Visual Acuity
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Mon 1 (n=108) Mon 3 (n=107) Mon 6 (n=105)
logMAR
Binocular UCVA (Mean, 95%CI)
Far Intermediate Near
European Post-Market IC-8® Study Outcomes
The IC-8 IOL is not approved for use in the United States

14. Virgin Eyes

15. 86.5%
7.5%
5.4%
0.3%
0.3%
Monofocal
Toric
Presbyopia-correcting
Phakic
Other
IC-8® IOL Opportunity
*Estimate based on prevalence of LVC, corneal aberrations > 0.5 microns and keratoconus and
reported 2016 US IOL adoption data from the 2016 Market Scope IOL Report
11%
Aberrated
Cornea Segment*
2016 Market Scope IOL Report – US IOL Adoption
The IC-8 IOL is not approved for use in the United States